Indeed, cetuximab, a monoclonal anti-epidermal growth factor receptor (EGFR) antibody, has been shown to improve median survival, when combined with cytotoxic chemotherapy in treatment of advanced HNSCC [8]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.